about
Application of metabolomics in drug resistant breast cancer researchEstrogen-Related Receptors in Breast Cancer and Prostate CancerKSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTLChallenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerThe human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ hybridizationGrowth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel.The emerging role of QSOX1 in cancerNILCO biomarkers in breast cancer from Chinese patientsCellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthPhotochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers.Molecular characteristics of recurrent triple-negative breast cancer.Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PKThe hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells.ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.Clinical applications of mouse models for breast cancer engaging HER2/neu.Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.Personalized therapy for breast cancer.Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.The effect of miR-340 over-expression on cell-cycle-related genes in triple-negative breast cancer cells.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy.Compounds from Dryopteris fragrans (L.) Schott with cytotoxic activity.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Different apoptotic effects of saxifragifolin C in human breast cancer cells.mTOR Inhibitors at a Glance.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesCDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer.Kinase-targeted cancer therapies: progress, challenges and future directions.E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancerThe "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
P2860
Q26866291-3A7F49A6-18A5-406F-B2BF-12243CFE2409Q28084030-2288BDEF-1FBB-4668-AA17-2E634B173377Q28831422-038EFC23-E368-4F1E-8256-A251DF75DCB1Q33576608-2B493C16-544A-4ECD-9C26-7DDE78A22066Q33692695-A3CEFDBE-FCC5-4211-B2DD-E1FC6F4DE143Q33696729-A64002EF-317F-4EF0-A654-40FBEB1040FCQ33828308-6B45F0BC-18AB-4658-9DB9-008E1E0D89B7Q33914001-8F789811-35C6-4485-99B5-449F3E6DE1B9Q34460429-BA9D86DC-8D71-4BA3-8C4A-7121AFE8C449Q35626610-836D034B-AA4B-4E02-B390-324AC832CDF5Q35828597-781D40F3-6F62-4CB3-B6E7-95466AC0376BQ35908698-9CDCDF8B-88CF-4D49-9040-B0A477A16ABBQ36224913-0A41A924-9EFC-438C-BFEF-5C51371FD957Q36688106-7F175997-1A1B-4373-B64F-74A7DB705797Q36962890-1380D4D4-29DC-4135-A1CD-514D3BBDEB80Q37190204-D6C00325-4002-4A19-B4D8-635E7F41A056Q37536415-D5202995-A26E-421E-A6FC-084E666DB149Q37607675-75009768-8DFE-4035-A0CF-2F6A4DC44239Q37636714-C63E8325-AAD8-4556-9E8B-51217B0D0C63Q37688324-CFC775A2-5038-4B68-892F-6A0FE6C797E2Q38196466-DC5053E1-C8D1-4EDF-B46C-CEC68C4C9D26Q38271490-35095D53-BA51-4F75-9D57-F3D09556BD3BQ38651952-3FC232C3-F5CA-4A20-8D7B-DB45CAE4CAB5Q38768253-AA72BA25-20A0-48A4-B06B-088BB961E212Q38888022-EEB935CA-4C03-4FDB-BFC4-BA5294ECA42AQ38945753-A110890A-1910-4586-A5A6-5249A1122B09Q38999344-6922227F-0004-4131-8B51-883AFD74315CQ39013860-20416480-20E2-40A7-97D9-57835ADFB986Q39113994-6F2559F4-469F-4FEE-B11C-652BDD06A8DDQ39930598-96138FF7-5192-4E9F-9AFD-75C5FF1C5DAAQ40760533-7163A426-355D-4767-93CC-B798A839D158Q41664067-8C6260ED-09BC-47F7-9392-A48CA4F526BCQ42704187-D0387364-7074-490E-A6BD-D3DF446283ACQ47119839-354488E1-81F5-44DF-A851-773EFCF525B1Q49516798-62D02C01-8FF7-4CA8-B1C6-E91B84E317F8Q49887882-7B1BF4E3-E1F9-4374-AF28-598FBC04AA33Q58603744-62C51E9D-03DA-4E80-B949-7F9561F75EE0Q58702607-0CC1D8D0-CAAF-4835-B9F0-E3041228AAD3
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeted therapy for breast cancer
@ast
Targeted therapy for breast cancer
@en
Targeted therapy for breast cancer
@nl
type
label
Targeted therapy for breast cancer
@ast
Targeted therapy for breast cancer
@en
Targeted therapy for breast cancer
@nl
prefLabel
Targeted therapy for breast cancer
@ast
Targeted therapy for breast cancer
@en
Targeted therapy for breast cancer
@nl
P2093
P3181
P1476
Targeted therapy for breast cancer
@en
P2093
Ali Mohamed
Burcu Cakar
Cynthia X. Ma
Kenneth Krajewski
P304
P3181
P356
10.1016/J.AJPATH.2013.07.005
P407
P577
2013-10-01T00:00:00Z